{"id":114928,"date":"2021-03-01T15:35:37","date_gmt":"2021-03-01T15:35:37","guid":{"rendered":"https:\/\/precoinnews.com\/?p=114928"},"modified":"2021-03-01T15:35:37","modified_gmt":"2021-03-01T15:35:37","slug":"stock-alert-aslan-pharma-jumps-30-on-positive-data-from-atopic-dermatitis-treatment-study","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/bitcoin\/stock-alert-aslan-pharma-jumps-30-on-positive-data-from-atopic-dermatitis-treatment-study\/","title":{"rendered":"Stock Alert: ASLAN Pharma Jumps 30% On Positive Data From Atopic Dermatitis Treatment Study"},"content":{"rendered":"
Shares of ASLAN Pharmaceuticals Limited (ASLN) jumped over 30% on Monday morning after the company announced positive interim data from a study of skin disease treatment.<\/p>\n
ASLN is currently trading at $5.89, up $1.46 or 32.96%, on the Nasdaq.<\/p>\n
ASLAN Pharma, a clinical-stage immunology focused biopharmaceutical company, announced positive interim data from study of ASLAN004 for the treatment of moderate to severe atopic dermatitis.<\/p>\n
ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.<\/p>\n
Atopic dermatitis usually develops in early childhood and is more common in people who have a family history of the condition. The main symptom is a rash that typically appears on the arms and behind the knees, but can also appear anywhere. <\/p>\n